Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Ulrich Mrowietz, Knud Kragballe, Kristian Reich et al. · Archives of Dermatological Research · 2010 · 868 citations · Full text

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp, Kristian Reich, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2015 · 649 citations · Full text

Autoimmune Disease, Medicine, Phase Iii +7

Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

Mark Lebwohl, H. Bachelez, Giampiero Girolomoni et al. · Journal of the American Academy of Dermatology · 2014 · 505 citations

Rheumatoid Disorder, Rheumatology, Disease Management +13

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

C. Paul, Jennifer Clay Cather, Melinda Gooderham et al. · British Journal of Dermatology · 2015 · 464 citations · Full text

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

Peter Schäfer · Biochemical Pharmacology · 2012 · 425 citations

Inflammation, Rheumatology, Autoimmune Disease +12